DPP4i vildagliptin, saxagliptin and linagliptin reduce IL-1ß and TNF-α in STZ-induced AD rats [220–222], with linagliptin also lowering TBARS and nitrite levels and increasing catalase activity [222]. Here, IL1A is linked to Alzheimer disease.